R. Brey

发表

Isolation and genetic characterizations of Bacillus megaterium cobalamin biosynthesis-deficient mutants

J. B. Wolf, R. Brey, Julie B. WOLFt, 1986, Journal of bacteriology.

Cloning of multiple genes involved with cobalamin (Vitamin B12) biosynthesis in Bacillus megaterium

J. B. Wolf, R. Brey, C. Banner, 1986, Journal of Bacteriology.

Molecular basis for improved anthrax vaccines.

R. Brey, Robert N Brey, 2005, Advanced drug delivery reviews.

Properties of Escherichia coli mutants altered in calcium/proton antiport activity

B. Rosen, R. Brey, 1979, Journal of bacteriology.

Cation/proton antiport systems in Escherichia coli.

B. Rosen, R. Brey, J. Beck, 1978, Biochemical and biophysical research communications.

Effect of single-point mutations on the stability and immunogenicity of a recombinant ricin A chain subunit vaccine antigen

J. Karanicolas, S. Joshi, D. Volkin, 2013, Human vaccines & immunotherapeutics.

A Monoclonal Immunoglobulin G Antibody Directed against an Immunodominant Linear Epitope on the Ricin A Chain Confers Systemic and Mucosal Immunity to Ricin

N. Mantis, Lori M. Neal, R. Brey, 2009, Infection and Immunity.

Development of vaccines based on formulations containing nonionic block copolymers.

R. Brey, 1995, Pharmaceutical biotechnology.

Thermostable ricin vaccine protects rhesus macaques against aerosolized ricin: Epitope-specific neutralizing antibodies correlate with protection

Iliodora V. Pop, N. Mantis, P. Didier, 2015, Proceedings of the National Academy of Sciences.

Comparative Efficacy of Two Leading Candidate Ricin Toxin A Subunit Vaccines in Mice

N. Mantis, R. Brey, Joanne M. O’Hara, 2013, Clinical and Vaccine Immunology.

A rapid, three-step process for the preformulation of a recombinant ricin toxin A-chain vaccine.

L. Peek, R. Brey, C. Middaugh, 2007, Journal of pharmaceutical sciences.

Targeting polymerised liposome vaccine carriers to intestinal M cells.

David J Brayden, B. Hirst, D. Brayden, 2001, Vaccine.

Fragmentation of colicins A and E1 by cell surface proteases

R. Brey, 1982, Journal of bacteriology.

Biophysical characterization and immunization studies of dominant negative inhibitor (DNI), a candidate anthrax toxin subunit vaccine

Vidyashankara G. Iyer, S. Joshi, D. Volkin, 2013, Human vaccines & immunotherapeutics.

Oral Salmonella typhimurium vaccine expressing circumsporozoite protein protects against malaria.

J. Ou, J. F. Young, S. Cryz, 1988, Science.

Combination of two candidate subunit vaccine antigens elicits protective immunity to ricin and anthrax toxin in mice.

N. Mantis, R. Brey, D. Vance, 2015, Vaccine.

Energy transduction in Escherichia coli: new mutation affecting the Fo portion of the ATP synthetase complex

B. Rosen, R. Brey, S. Hasan, 1978, Journal of bacteriology.

Cation/proton antiport systems in Escherichia coli. Properties of the potassium/proton antiporter.

B. Rosen, R. Brey, E. Sorensen, 1980, The Journal of biological chemistry.

Cation/proton antiport systems in Escherichia coli. Properties of the calcium/proton antiporter.

B. Rosen, R. Brey, 1980, The Journal of biological chemistry.

Ricin: A Type II Ribosome-Inactivating Protein

N. Mantis, R. Brey, 2009 .

Clinical and Pathological Findings Associated with Aerosol Exposure of Macaques to Ricin Toxin

S. Pincus, M. Bhaskaran, P. Didier, 2015, Toxins.

The FDA animal efficacy rule and biodefense

Gigi Kwik Gronvall, Luciana Borio, G. Gronvall, 2007, Nature Biotechnology.

Seneca Valley Virus Exploits TEM8, a Collagen Receptor Implicated in Tumor Growth

David J. Evans, B. St. Croix, R. Brey, 2018, Front. Oncol..

LT-IIb(T13I), a Non-Toxic Type II Heat-Labile Enterotoxin, Augments the Capacity of a Ricin Toxin Subunit Vaccine to Evoke Neutralizing Antibodies and Protective Immunity

Christopher J. Greene, N. Mantis, T. D. Connell, 2013, PloS one.

Binding of the von Willebrand Factor A Domain of Capillary Morphogenesis Protein 2 to Anthrax Protective Antigen Vaccine Reduces Immunogenicity in Mice

A. Casadevall, R. Brey, J. Bann, 2020, mSphere.

Stabilization of a recombinant ricin toxin A subunit vaccine through lyophilization.

Lilia A. Rabia, Kimberly J. Hassett, N. Mantis, 2013, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

New frontiers in vaccines for emerging pathogens.

R. Brey, H. Oya Alpar, 2005, Advanced drug delivery reviews.

Phase I clinical trials of aroA aroD and aroA aroD htrA attenuated S. typhi vaccines; effect of formulation on safety and immunogenicity.

S. Cryz, A. Lindberg, R. Brey, 2000, Vaccine.

Oral delivery of antigens in live bacterial vectors.

R. Brey, M. Sabara, D. Dilts, 1991, Advances in experimental medicine and biology.

Structure of RiVax: a recombinant ricin vaccine

P. M. Legler, E. Vitetta, C. Millard, 2011, Acta crystallographica. Section D, Biological crystallography.

Polymerized liposomes : From biophysics to applications. Part II

D. Lasič, R. Brey, E. Bolotin, 2000 .

Folding domains within the ricin toxin A subunit as targets of protective antibodies.

N. Mantis, R. Brey, Joanne M. O’Hara, 2010, Vaccine.

Recent advances in the development of vaccines against ricin

Leonard A. Smith, S. Pincus, N. Mantis, 2016, Human vaccines & immunotherapeutics.

Structure of RiVax: a recombinant ricin vaccine

P. M. Legler, R. Brey, Joan E. Smallshaw, 2011, Acta crystallographica. Section D, Biological crystallography.